Skip to main content
    A

    Ascendis Pharma AS (ASND)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $271.73
    -3.66 (-1.33%)

    Market Cap: $18.06B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Ascendis Pharma AS (ASND) Financials: Revenue, Profit and Cash Flow

    Updated Nov 12, 2026. Financial statements from company filings, amounts in EUR.

    Ascendis Pharma AS reported revenue of EUR 691.71M for the fiscal year ended Dec 31, 2025, up 90.2% from the year before. That year, net income was EUR -219.03M with a net margin of -31.7%, operating cash flow was EUR 51.77M and free cash flow was EUR 43.62M. The quarter ended Sep 30, 2026 had revenue of EUR 367.46M and net income of EUR 73.53M.

    Revenue and Margins

    The operating margin was -18.9% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from EUR 4.61M, a compound annual rate of 74.5%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025691.71M+90.2%85.1%-18.9%-31.7%
    Dec 2024363.64M+36.3%87.8%-76.7%-104.0%
    Dec 2023266.72M+421.2%83.4%-170.8%-180.5%
    Dec 202251.17M+557.9%76.3%-1097.9%-1139.6%
    Dec 20217.78M+11.9%54.7%-5808.6%-4931.6%
    Dec 20206.95M-48.0%100.0%-4755.1%-6025.5%
    Dec 201913.38M+26.4%100.0%-1695.1%-1630.0%
    Dec 201810.58M+591.6%100.0%-1462.6%-1229.5%
    Dec 20171.53M-66.8%100.0%-7290.3%-8097.8%
    Dec 20164.61MN/A100.0%-1583.2%-1487.3%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, net income turned positive after a loss in the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue691.71M363.64M266.72M51.17M7.78M6.95M13.38M10.58M1.53M4.61M
    Cost of revenue103.18M44.26M44.40M12.14M3.52M000N/AN/A
    Gross profit588.53M319.38M222.32M39.04M4.25M6.95M13.38M10.58M1.53M4.61M
    Research and development283.50M307.00M413.45M379.62M295.87M260.90M191.62M140.28M99.59M66.02M
    Operating income-130.89M-278.76M-455.54M-561.81M-451.79M-330.62M-226.72M-154.76M-111.54M-72.92M
    Net income-219.03M-378.08M-481.45M-583.19M-383.58M-418.95M-218.02M-130.10M-123.90M-68.50M
    EBITDA-109.80MN/A-411.17M-529.18M-364.64MN/A-210.34M-129.48MN/A-68.05M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue367.46M344.90M250.66M245.18M213.63M158.04M100.95M173.92M57.83M36.00M95.89M137.70M
    Gross profit335.16M312.61M229.03M217.98M191.28M126.60M83.44M159.89M46.63M24.53M88.33M118.25M
    Operating income123.84M63.43M25.22M9.80M11.00M-52.95M-104.21M383.00K-96.74M-133.26M-49.15M-36.61M
    Net income73.53M210.40M639.69M-33.25M-60.99M-38.85M-94.63M-38.47M-99.20M-109.38M-131.03M-86.88M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of EUR 871.58M exceeded cash and equivalents by 255.80M. Shareholder equity was negative, at -162.75M, as total liabilities of 1.46B exceeded total assets of 1.30B.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets1.30B1.18B825.59M1.09B1.08B979.79M676.73M318.97M210.98M190.07M
    Current assets1.11B1.06B702.72M923.47M805.89M740.13M611.17M292.91M204.63M183.96M
    Cash and equivalents615.78M559.54M392.16M444.77M446.27M584.52M598.11M277.86M195.35M180.33M
    Total liabilities1.46B1.29B971.28M826.39M201.29M141.08M79.62M38.92M23.77M13.46M
    Short-term debt486.32M491.54M435.44M426.77M13.99M6.86M5.90M000
    Long-term debt385.25M365.08M534.25M482.96M97.97MN/A0000
    Shareholder equity-162.75M-105.71M-145.70M263.35M883.63M838.71M597.11M280.05M187.21M176.61M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets2.47B2.29B2.01B1.30B1.15B1.09B1.06B1.18B1.09B758.30M802.50M825.59M
    Total liabilities942.42M849.18M1.52B1.46B1.33B1.28B1.25B1.29B1.19B1.08B1.04B971.28M
    Cash and equivalents980.69M811.92M573.42M615.78M539.09M494.05M517.92M559.54M625.51M258.70M320.24M392.16M
    Shareholder equity1.53B1.44B488.48M-162.75M-174.07M-187.57M-189.81M-105.71M-97.32M-321.13M-238.18M-145.70M
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 84.3% of operating cash flow.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow51.77M-306.20M-467.36M-495.70M-417.65M-271.55M-175.94M-138.80M-95.10M-60.18M
    Capital expenditures8.15M1.43M2.44M14.49M24.23M21.55M5.16M2.65M941.00K672.00K
    Free cash flow43.62M-307.62M-469.80M-510.19M-441.88M-293.10M-181.09M-141.45M-96.04M-60.85M
    Dividends paidN/AN/AN/A5.06M33.14MN/A0000
    Investing cash flow-8.15M6.88M286.47M61.73M-110.58M-291.20M-5.16M-2.65M-941.00K-672.00K
    Financing cash flow34.89M443.93M134.29M396.77M351.39M602.65M493.59M203.27M124.72M117.46M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow184.70M286.35M-7.85M70.67M2.15M-7.34M-14.31M-87.18M-56.13M-61.31M-101.58M-42.47M
    Capital expenditures2.63M3.24M7.84M3.30M53.00K4.34M703.00K383.00K467.00K342.00K199.00K63.00K
    Free cash flow182.07M283.11M-15.69M67.37M2.10M-11.68M-15.02M-87.56M-56.60M-61.65M-101.78M-42.53M
    Last 12 quarters

    Frequently Asked Questions About ASND

    What is Ascendis Pharma AS's annual revenue?

    Ascendis Pharma AS reported revenue of EUR 691.71M for the fiscal year ended Dec 31, 2025.

    How fast is Ascendis Pharma AS's revenue growing?

    Revenue was up 90.2% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 138.2%.

    Is Ascendis Pharma AS profitable?

    No. Ascendis Pharma AS reported net income of EUR -219.03M for the fiscal year ended Dec 31, 2025, with a net margin of -31.7%.

    How much free cash flow does ASND generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of EUR 51.77M minus capital expenditures of EUR 8.15M produced free cash flow of EUR 43.62M.

    How much debt does Ascendis Pharma AS have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of EUR 385.25M, short-term debt of EUR 486.32M and cash and equivalents of EUR 615.78M.